Literature DB >> 7524068

Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas.

K Fudge1, C Y Wang, M E Stearns.   

Abstract

The purpose of this study was to determine whether changes in the expression of platelet-derived growth factor (PDGF) and its receptors were associated with prostate cancer. Peroxidase-anti-peroxidase-immunoperoxidase labeling was used to detect the A and B chains and alpha and beta receptors of PDGF in 5 benign prostatic hyperplasias and 13 human prostate adenocarcinomas (Gleason grades 2 to 9). In all 5 benign prostatic hyperplasias, none of the PDGF antibodies (even at high titers, 1:50 dilutions) labeled the epithelial or the stromal cells. In adenocarcinomas, the A chain and alpha receptor antibodies labeled both epithelial and stromal cells. The intensity of the staining was relatively high in low Gleason grade (<6) and low in high Gleason grade (>7) tissue; however, the B chain and beta receptor antibodies failed to label either epithelial or stromal cells in any of the 13 adenocarcinomas. The data suggest that PDGF A and alpha receptor genes may be preferentially turned on in epithelial and stromal prostate tumor cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524068

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

Review 2.  Progress of molecular targeted therapies for prostate cancers.

Authors:  Weihua Fu; Elena Madan; Marla Yee; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2011-11-29

3.  A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.

Authors:  Carolyn V Ustach; Wei Huang; M Katie Conley-LaComb; Chen-Yong Lin; Mingxin Che; Judith Abrams; Hyeong-Reh Choi Kim
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

4.  Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.

Authors:  Ju-Won Roh; Jie Huang; Wei Hu; XiaoYun Yang; Nicholas B Jennings; Vasudha Sehgal; Bo Hwa Sohn; Hee Dong Han; Sun Joo Lee; Duangmani Thanapprapasr; Justin Bottsford-Miller; Behrouz Zand; Heather J Dalton; Rebecca A Previs; Ashley N Davis; Koji Matsuo; Ju-Seog Lee; Prahlad Ram; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

5.  The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.

Authors:  Mike R Russell; Qingxin Liu; Hetian Lei; Andrius Kazlauskas; Alessandro Fatatis
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

6.  Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.

Authors:  Abdo J Najy; Young Suk Jung; Joshua J Won; M Katie Conley-LaComb; Allen Saliganan; Chong Jai Kim; Elisabeth Heath; Michael L Cher; R Daniel Bonfil; Hyeong-Reh Choi Kim
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

7.  Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor.

Authors:  Nathan G Dolloff; Shannon S Shulby; Autumn V Nelson; Mark E Stearns; Gregg J Johannes; Jeff D Thomas; Olimpia Meucci; Alessandro Fatatis
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

8.  A critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate.

Authors:  Michael Christensen; Abdo J Najy; Michael Snyder; Lisa S Movilla; Hyeong-Reh Choi Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

9.  Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer.

Authors:  Robert E Brown; George Zotalis; Ping L Zhang; Bihong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 10.  Bone metabolism and new targets for intervention.

Authors:  Bulent Akduman; E David Crawford
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.